Canadian-based Tetra Bio-Pharma is taking a pharmaceutical pathway to discover and develop cannabinoid-derived pharmaceuticals.
Being a global biopharmaceutical leader in cannabinoid-based drug discovery and development, Tetra Bio-Pharma is well-recognised for their accelerated regulatory achievements, clinical programs and cost management. And they’re well on their way to delve further into the world of cannabinoid-derived pharmaceuticals.
Tetra’s core competencies lie in their deep and longstanding pharmaceutical industry knowledge and experience in bringing pharmaceutical products to market.
Additionally, their differentiation can be attributed to the benefits associated with ‘late-stage’ status, allowing them to bypass conventional pharmaceutical testing and approval processes vastly reducing drug development costs. Tetra Bio-Pharma is the only company in North America, other than GW Pharma, working with Health Canada and the FDA on clinical trial programs with cannabinoid-derived pharmaceuticals . These trials have led to a significantly improved understanding of the safety, pharmacokinetics and pharmacodynamics of cannabinoid-based drugs targeted for the treatment of pain. As their products continue to advance through various phases of clinical development, Tetra Bio-Pharma is delivering on the need for rigorous scientific evidence while at the same time building shareholder value with the introduction of cannabinoid-based natural health products.
The vital role of cannabinoid-derived pharmaceuticals
Currently cannabis plays an important role in the treatment of some of the main symptoms reported by cancer patients, such as insomnia, loss of appetite, depression, nausea and vomiting and may also help to relieve chronic pain, cancer pain, breakthrough cancer pain and neuropathic pain including fibromyalgia as well as ocular pain.
While it is a widely believed that cannabis has the potential to be of therapeutic benefit, there is no scientific safety and efficacy data to prove it. Not only is this an enormous barrier for physicians whose training is predicated on evidence-based medicine, but it is also an obstacle for professional associations as well as public and private insurers.
Until and unless cannabinoid-derived pharmaceuticals can meet the stringent standards for drug approval, access to cannabinoid-derived medicines will not find their way into the mainstream medical system and not likely covered by health insurance.
The Company is focused on three core therapeutic areas including oncology, chronic pain and opthalmic. Tetra Bio-Pharma combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.